For further details on collaborations within the SFB-F61, SFB-F47, ERA PerMed JAKSTAT-TARGET or ERANET-PLL network grants please follow the links.
National
Dr. Fritz Aberger, University Salzburg, Skin cancer and hedgehog/JAK-STAT crosstalk
Dr. Walter Berger,Medical University of Vienna, Translational cancer research and Comparative Genome Hybridization of patient-derived cancer cell lines
Dr. Michael Bergmann, Medical University Vienna, Colorectal cancer and chronic inflammatory gastrointestinal tract disease
Dr. Andreas Bergthaler, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Work on Tasmanian Devil Facial Tumor Disease and viral pathogenesis/antiviral immune responses
Dr. Christoph Bock, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Bioinformatics and gene expression analysis
Dr. Thomas Decker, Max Perutz Labs Vienna, STAT transcription factors in chromatin
Dr. Helmut Dolznig, Medical University Vienna, WNT signalling and colorectal cancer research
Dr. Florian Grebien, University of Veterinary Medicine, Vienna, Work on acute leukemias and targeting driver mutation products
Dr. Lukas Kenner, University of Veterinary Medicine, Vienna, Oncogenic STAT3/5 in prostate cancer and T cell neoplasms, histo-pathology and molecular pathology
Dr. Kristaps Klavins, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Metabolomics in T cell neoplasia
Dr. Heinrich Kovar, Children’s Cancer Research Institute Vienna, Sarcoma research and establishment of a mouse model for Ewing´s Sarcoma
Dr. Andrey Kozlov, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Reactive Oxygen Species, liver damage and Nitric Oxide analyses
Dr. Robert Kralovics, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Myeloproliferative mouse models and JAK2V617F oncogene signalling
Dr. Stefan Kubicek, CeMM – Research Center for Molecular Medicine of the Austrian Academy of Sciences, Chemical screening, drug target identification and metabolomics
Dr. Grazyna Kwapiszewska / Dr. Leigh Marsh, Ludwig Boltzmann Institute for Lung Vascular Research, Lung vascular research and thromboembolism
Dr. Mario Mikula, Medical University Vienna, Melanoma research
Dr. Wolfgang Mikulits, Medical University Vienna, Liver cancer research
Dr. Mathias Müller, University of Veterinary Medicine, Vienna, TYK2 tyrosine kinase and transgenesis
Dr. Jan Michael Peters, Research Institute of Molecular Pathology, Higher order chromatin structures with STAT5 transcription factors
Dr. Thomas Rülicke, University of Veterinary Medicine, Vienna, Transgenesis and developing mouse models
Dr. Veronika Sexl, University of Veterinary Medicine, Vienna, JAK-STAT in cancer, acute leukemia resistance mechanisms and CDK6 kinase in cancer
Dr. Karl Sotlar, Uniklinikum Salzburg, Myeloproliferative neoplasm pathology
Dr. Birgit Strobl, University of Veterinary Medicine, Vienna, STAT1 transcription factor signalling
Dr. Peter Valent / Dr. Emir Hadzijusufovic, Medical University Vienna, Acute leukemias, thromboembolism and myeloproliferative neoplasms, targeting driver oncogenes
Dr. Peter Wolf, Department of Dermatology and Venereology, Medical University of Graz, Translational work on Cutaneous T cell Leukemia, Sezary syndrome and Mycosis Fungoides
International
Dr. Vasileios Bekiaris, Technical University of Denmark, Lyngby, Denmark, Role of STAT5 in T cell biology and autoimmune disease
Dr. Kevin D. Bunting, Emory University, Atlanta, USA, Interference with inhibitors of the PI3K-AKT-mTOR cascade and oncogenic STAT5 action in neoplastic cells
Dr. Stefan Constantinescu, Ludwig Cancer Institute, De Duve Institute, Brussels, Belgium, p53 mutations and interaction with STAT5 in myeloproliferative neoplasms and acute leukemias
Dr. Michael Deininger, Utah Huntsman CI, Salt Lake City, USA, STAT3/5 in the evolution, progression and targeting of chronic myeloid leukemia
Dr. Maria Fragiadaki, Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, The Medical School, University of Sheffield, Sheffield, England
Dr. Karlheinz Friedrich, Institute for Biochemistry, Friedrich Schiller University Jena, Jena, Germany, Colorectal cancer research
Dr. F. Gouilleux, Université Rabelais, Tours, France, STAT5 in leukemogenesis and PI3K-AKT-mTOR signaling, and proteolytic targeting of STAT5
Dr. Patrick T. Gunning / Dr. Elvin de Araujo, University of Toronto, Mississauga, Canada, Drug discovery based on key components of core cancer pathways
Dr. Xiaonan Han, Division of Hematology and Oncology, and Division of Cancer Biology, MetroHealth Medical Center (MHMC), Case Western Reserve University (CWRU) School of Medicine, Cleveland, OH, USA, STAT5 signaling in the gastrointestinal inflammation, infection and neoplasia.
Dr. Lothar Hennighausen, National Institutes of Health, Washington, USA, Immunity and cancer insights, mouse models of STAT5 function
Dr. Marco Herling, University of Cologne, Cologne, Germany, JAK-STAT signaling in T cell neoplasms and cancer cell metabolism
Dr. György M. Keserü, Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Budapest, Hungary, JAK-STAT inhibitors
Dr. Joe Lewis, European Molecular Biology Laboratory, Heidelberg, Germany, Chemical Biology Core Facility, Chemical biology
Dr. A. Thomas Look, Dana Farber, Boston, USA, T cell acute lymphoblastic leukemia, anaplastic large cell lymphoma and mutated JAK kinases
Dr. Satu Mustjoki, University of Helsinki, Helsinki, Finland, JAK-STAT signaling in mature T cell neoplasms
Dr. Gerhard Müller-Newen, Rheinisch-Westfälische Technische Hochschule Aachen, Germany, STAT5 shuttling in acute leukemias
Dr. John O’Shea, National Institutes of Health, Washington, USA, STAT5 function in T cells
Dr. Josef Prchal, University of Utah, USA, Myeloproliferative neoplasms and thrombosis research
Dr. William Tse, Metro Health Cancer Center, Case Western Reserve University, Ohio, USA, AF1q in carcinoma metastasis
Dr. Jan Tuckermann, University of Ulm, Ulm, Germany, Stress hormone receptor-STAT5 axis for metabolic control
Dr. K.U. Wagner, Wayne State University, Detroit, USA, JAK2-STAT5 signaling and transgenic mouse models
The Moriggl Lab 